Abivax Stock Climbs 3.14% at Close with Record Annual Surge
The stock of French biotech company Abivax closed the session on Wednesday, November 26 at 111.80 euros, up 3.14% from the previous day when it traded at 108.40 euros. This increase occurs in a context of stock market euphoria for the company, which has shown an exceptional annual performance of 1,270%, marking the best progress in the SBF 120 since the beginning of January. Trading volumes remain robust with 0.29% of the capital exchanged, while the CAC 40 index ended up 0.88% at 8,096.43 points.
Short-Term Upward Trajectory Continues
Abivax's stock continues its short-term upward trajectory, with a weekly gain of 13.27% and a surge of 70.95% over the last three months. These performances place the stock in a sustained bullish dynamic, significantly outperforming the CAC 40, which has an annual gain of 11.56%. The current price is well above the 50-day moving average set at 82.77 euros, and even more so from the 200-day moving average at 37.05 euros. This setup demonstrates a solidly upward trend over several months. The monthly volatility of 20.06 reflects the amplitude of daily fluctuations on the stock, characteristic of biotechnological values in advanced clinical phases. The resistance threshold now surpasses 108.40 euros, a major technical barrier and corresponding to the previous day's closing price, while the support is positioned at 76.10 euros. The structure of the 50 and 200-day moving averages, with a gap of about 45 points, confirms the strength of the ongoing bullish movement.
Technical Analysis Reveals a Mixed Situation
Technical analysis reveals a mixed situation for the stock. On one hand, the RSI at 77 indicates a pronounced overbought zone, suggesting that the stock might undergo a phase of consolidation or technical correction in the short term. This reading is confirmed by the positioning of the price near the upper Bollinger band established at 108.92 euros, with the stock evolving in the upper part of its volatility channel. On the other hand, the MACD displays positive signals with a MACD line at 6.39 above the signal line at 4.87, while the MACD histogram in positive territory at 1.52 confirms the persistence of the bullish dynamic. The Scholes buy signal corroborates this favorable technical reading. The CMF (Chaikin Money Flow) indicator at 0.04 reveals a slightly positive monetary flow, while the OBV (On Balance Volume) in negative territory at -227,901 suggests some caution from investors despite recent gains. This divergence between price and cumulative volumes deserves attention in upcoming sessions. The lower Bollinger band at 78.34 euros defines an expanded support zone in case of a pullback.
Shareholder Dynamics and Institutional Interest
On the shareholder front, Sofinnova Crossover I SLP has crossed upwards the threshold of 10% of voting rights, demonstrating the interest of institutional investors specialized in biotechnologies. Concurrently, two net short positions representing about 0.51% of the capital remain active on the stock, a relatively moderate level that does not pose an immediate threat. A purchase of 35,456 shares by executives has also been recorded, a signal generally interpreted as a vote of confidence from the management. The current valuation incorporates investors' anticipation regarding the results of phase 3 trials of the drug candidate obefazimod in the treatment of ulcerative colitis, whose initial data presented in July 2025 were well received by the market. With a beta of -2.36, the negative correlation with the market underscores the speculative nature of the stock, more driven by its own clinical catalysts than by general market trends. Investors remain attentive to the next regulatory steps and maintenance data expected in the second quarter of 2026.
